Canine

Meloxicam for Canine Osteoarthritis Pain: Efficacy, Safety, and 2025 Head-to-Head vs. Bedinvetmab

Jul 2, 2026 6 min read
Updated Nov 3, 2026AI-generated clinical reference · Sources and methodology

Bottom line

  • Meloxicam is a COX-2-preferential NSAID with the most extensive published efficacy dataset among NSAIDs for canine osteoarthritis (OA), supported by multiple pivotal randomized controlled trials.
  • A 2025 randomized open-label comparison in 101 dogs found improvement in both groups without a statistically significant between-group efficacy difference. This superiority-design trial did not establish equivalence or non-inferiority. More adverse events were reported with meloxicam (17 versus 4). [1]
  • Standard dog dose: 0.2 mg/kg PO on day 1 (loading), then 0.1 mg/kg PO once daily for maintenance; follow the formulation-specific administration instructions and use the lowest effective dose. [4]
  • Periodic monitoring of renal function (BUN, creatinine, urinalysis) and liver enzymes is recommended in dogs on chronic meloxicam therapy, particularly those with pre-existing renal disease, dehydration risk, or concurrent medications.
  • Meloxicam injectable (Metacam) is approved for a single dose in cats (0.3 mg/kg SC) for post-surgical pain; chronic oral meloxicam in cats is NOT approved in the US due to renal toxicity risk, though used long-term in some countries with strict monitoring.
  • This is a clinician-facing evidence summary. It is not a treatment protocol; confirm drug dosing, species-specific label restrictions, and monitoring protocols against current formularies and your hospital protocols.

From reading to clinical reasoning

Pressure-test the decisions behind this article

Open Clinical Desk with the public topic prefilled. Add patient context only after you are inside the secure vet workspace.

meloxicam canine osteoarthritis pain

Patient details stay inside the authenticated workspace.

Clinical facts

  • Drug class: COX-2-preferential NSAID; inhibits prostaglandin synthesis preferentially via COX-2 over COX-1, reducing inflammatory mediator production in joint tissue.
  • Indications (dogs): Canine OA pain and inflammation (FDA-approved, Boehringer Ingelheim, Metacam/Loxicom); perioperative pain. Oral solution (0.5 mg/mL), chewable tablets, and injectable forms available.
  • Dosing (dogs): Loading dose 0.2 mg/kg PO Day 1; maintenance 0.1 mg/kg PO once daily. Follow the product-specific instructions for food/syringe administration and use the lowest effective dose. [4]
  • Cat restriction: Injectable meloxicam is approved in the US for single SC use in cats (0.3 mg/kg) for perioperative pain only. Repeated dosing or oral meloxicam is NOT approved in the US cats due to documented nephrotoxicity risk; foreign product authorizations and professional guidelines must be checked separately; AAFP guidance is not a drug label. This distinction is critical for US practitioners.
  • Contraindications: Active GI ulceration, pre-existing renal insufficiency or dehydration, hepatic failure, coagulopathies, concurrent NSAID or corticosteroid use. Never combine NSAIDs.
  • Adverse effects (dogs): GI signs most common (vomiting, diarrhea, anorexia, melena); renal papillary necrosis at supratherapeutic doses or in volume-depleted patients; hepatotoxicity reported rarely.
  • Drug interactions: Avoid concomitant NSAIDs or corticosteroids; other medications affecting renal perfusion require careful assessment. The label calls for appropriate washout times when switching from corticosteroids or another NSAID but does not specify a universal 5-day interval. Select the interval using the prior drug, exposure, patient status and applicable labeling. [4]

What the evidence shows

Pivotal clinical efficacy studies

Placebo-controlled studies support meloxicam efficacy in canine OA. Peterson and Keefe reported improvement in clinical condition compared with placebo. [2] Doig and colleagues also evaluated clinical efficacy and tolerability in dogs with chronic OA. [3] These trials should be cited directly rather than conflated with carprofen studies or attributed to different authors.

Comparative trial vs. bedinvetmab (2025)

Innes et al. (2025) conducted a randomized, open-label, parallel-group trial in 101 client-owned dogs, with 52 allocated to bedinvetmab and 49 to meloxicam. The study tested a superiority hypothesis; it was not a non-inferiority or equivalence trial. Both groups improved in Canine Orthopaedic Index scores relative to baseline. The larger mean reduction with bedinvetmab was not statistically significant between groups. Four adverse events were reported with bedinvetmab and 17 with meloxicam, nine of the latter gastrointestinal. Forty-four bedinvetmab dogs and 33 meloxicam dogs completed the study. These results describe this trial population and do not establish equal efficacy or universal safety superiority. [1]

Implications for multimodal OA management

Meloxicam is an evidence-supported NSAID option for appropriately selected dogs with OA. The 2025 comparison did not detect a statistically significant efficacy difference; absence of a significant difference is not proof of equivalence or non-inferiority. [1] Active gastroduodenal ulceration requires treatment of the underlying disease and an analgesic plan that avoids adding another NSAID. A COX-2-selective NSAID plus gastroprotection must not be presented as a workaround for an active ulcer. The meloxicam label warns of GI ulceration/perforation and advises considering a non-NSAID/non-corticosteroid analgesic when additional pain control is needed. [4]

How this fits clinical practice

Selection should weigh comorbidities, concurrent medication, previous adverse reactions, ability to monitor, and client preferences. Neither the comparative trial nor COX selectivity establishes that an NSAID is safe in a patient with active GI ulceration. Review individual GI, renal and hepatic risk before treatment. Use the lowest effective dose for the shortest duration consistent with response, with baseline and periodic laboratory monitoring as the label recommends; reassessment intervals should be individualized. [4]

Always confirm specific dosing, species label restrictions (especially cats), and monitoring protocols against current formulary and product labeling.

Frequently Asked Questions

What is the standard meloxicam dose for a dog with osteoarthritis?

The U.S. Metacam oral-suspension label specifies 0.2 mg/kg orally on the first day only, then 0.1 mg/kg once daily. Follow its formulation- and weight-specific administration instructions and use the lowest effective dose for the shortest duration consistent with response. [4]

Is meloxicam as effective as bedinvetmab (Librela) for canine osteoarthritis?

Both groups improved in the 2025 randomized open-label trial, and the between-group efficacy difference was not statistically significant. The study tested superiority, not non-inferiority or equivalence, so it does not prove equal efficacy. More adverse events were reported with meloxicam in that trial. [1]

What are the contraindications for meloxicam in dogs?

Meloxicam is contraindicated in dogs with active GI ulceration, pre-existing renal insufficiency or dehydration, hepatic failure, or coagulopathies, and in patients on concurrent NSAID or corticosteroid therapy. NSAIDs should never be combined.

What monitoring is recommended for dogs on chronic meloxicam?

Obtain a history, examination, and baseline hematology/biochemistry before NSAID treatment, and monitor periodically during administration. Individualize the interval and reassess promptly for vomiting, diarrhea, appetite change, melena or other suspected adverse effects. [4]

Can meloxicam be used in cats?

In the US, injectable meloxicam is approved only for a single SC dose (0.3 mg/kg) in cats for perioperative pain; repeated dosing and oral meloxicam are NOT approved due to documented nephrotoxicity risk. Some countries permit chronic low-dose meloxicam in cats under strict renal monitoring, but this is a critical species-specific distinction for US practitioners.

What are the most common adverse effects of meloxicam in dogs?

Gastrointestinal signs are most common, including vomiting, diarrhea, anorexia, and melena. Renal papillary necrosis can occur at supratherapeutic doses or in volume-depleted patients, and hepatotoxicity is reported rarely.

Which drug interactions increase the risk of meloxicam in dogs?

Avoid concurrent NSAIDs or corticosteroids. Drugs affecting renal perfusion require assessment. The U.S. label calls for appropriate washout times when switching from corticosteroids or another NSAID; it does not specify one universal 5-day interval. Individualize the interval to the prior drug and patient. [4]

When should a clinician consider an alternative to meloxicam for canine OA?

Reconsider NSAID treatment when there is active GI ulceration, significant renal risk, dehydration, or problematic concurrent medication. Treat the underlying condition and choose an individualized analgesic plan. A COX-2-selective NSAID plus a gastroprotectant is not an established safe workaround for active ulceration; consider non-NSAID/non-corticosteroid analgesic options rather than stacking anti-inflammatory drugs. [4]

Changelog

  • 2026-07-02: First published.

References

  1. Innes JF, Lascelles BDX, Bell D, et al. A randomised, parallel-group clinical trial comparing bedinvetmab to meloxicam for the management of canine osteoarthritis. Front Vet Sci. 2025;12:1502218. (2025)
  2. Peterson KD, Keefe TJ. Effects of meloxicam on severity of lameness and other clinical signs of osteoarthritis in dogs. J Am Vet Med Assoc. 2004;225(7):1056-1060. (2004)
  3. Doig PA, Purbrick KA, Hare JE, McKeown DB. Clinical efficacy and tolerance of meloxicam in dogs with chronic osteoarthritis. Can Vet J. 2000;41(4):296-300. (2000)
  4. Metacam (meloxicam oral suspension) — U.S. prescribing information for dogs (accessed November 2026) (2026)

More clinical updates